The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks Jerry,
in the scale of the whole ( years of exploration, proving the resource, financing, mine build etc) I would have thought it would not be too hard to cut out the traders and go straight to smelters.
But what do I know eh
Afternoon Iceberg, that’s more what I trying
to say in my post, anyone how funds the 150m will want to know how they plan on getting the 2.7BN in order for them to see a return so if they (whoever they are) are happy to fund the 150m on what they see it would be logical to that they would lend the full amount subject to pretty heavy T&Cs, basically a loan in principle for the full amount, could even be in the form of an MOU
Thanks quady, addicknt ,
I largely agree with you both, but at the same time I can’t see the financier(s) not wanting a bigger piece of the pie and NM not being able to get a package for the whole lot with some heavy conditions and milestones etc, maybe that just suits my desires though lol ,
Best of luck guys
I’ve sold the lot, got out with a small profit thankfully but nothing like it could have been a few days ago, this a great company in my opinion and will go places but I can also see it drift lower over the next few days, and the amount of times I’ve watched profits evaporate and turn into losses while waiting for the news which is slightly delayed and then very delayed has swayed me to sell up and hope to buy back in lower around 3.5/4.
Good luck to you guys holding tight.
Hi all, can anyone advise what the state of play is with the appeal in Sweden, as per the rns 14th jan 19, the company were to appeal the decision of the cab but I can’t seem to find any further update.
Thanks in advance
“We believe our humanised mice give us a significant advantage in creating anti bodies for vivid-19 “ https://youtu.be/EqDnf_lEtgA
Also the company RNS states “ Using its humanized mice, the Advanced peripheral blood Hematopoietic Chimera ("ApbHC"), which were developed to model blood and autoimmune diseases and to test treatments, Hemogenyx will seek to discover human neutralizing antibodies - antibodies that are typically developed by the human immune system to neutralize invading viral pathogens - that could be used to fight SARS-CoV-2 (the virus that causes COVID-19) infections.
Prior to the appearance of COVID-19, Hemogenyx had been working independently and with a number of pharmaceutical company partners to utilize the exceptional features of ApbHC to identify and isolate human neutralizing antibodies for use as antiviral therapies. The Company's methodology is generally applicable to new pathogens including viruses, as previously described in the Company's original announcement of the development of ApbHC.
A man of this Calibre does NOT undertake the position of Chairman of any old little company that does not show the promise in medical breakthrough of which he has dedicated his entire working life towards.
Sir Marc has advised more than 20 of the largest pharmaceutical and biotech companies in the world and has mentored some of the most successful scientists, many of whom have become senior figures in the commercial pharmaceutical world. Sir Marc was knighted in the 2010 Queen’s Birthday and was in Australia with the knighthood equivalent, the Companion of the Order of Australia.
His work in London led to the generation of a new hypothesis for the mechanism of autoimmunity, linking upregulated antigen presentation and cytokine expression. Testing this hypothesis led to the discovery, with colleague Sir Ravinder Maini, of the pivotal role of TNFa (Tumor Necrosis Factor alpha) in the pathogenesis of rheumatoid arthritis. This major discovery has therapy not only of rheumatoid arthritis but other chronic inflammatory diseases (eg Inflammatory bowel disease, psoriasis, ankylosing spondylitis), and helped change the perception of monoclonal antibodies from niche products to mainstream therapeutics. Anti-TNF therapeutics are the current leading drug class with 2016 sales exceeding $36 Billion.
Great post and worth highlighting , but the CO v works really is just the tip of the ice berg. I hope all have researched the Marc field man and Michael Shepard, they are the best in the field the world over and they don’t jump onto little companies without knowing what they are capable off- ie turning into billion dollar companies.